CD4^LVFOXP3 in Participants With IPEX

Recruiting now · Phase 1

Conditions studied: IPEX

In brief

This first-in-human, Phase 1 clinical trial will test the feasibility of the manufacturing and the safety of the administration of CD4\^LVFOXP3 in up to 30 evaluable human participants with IPEX and evaluate the impact of the CD4\^LVFOXP3 infusion on the disease.

Key facts

Study ID
NCT05241444
Run by
Bacchetta, Rosa, MD
People needed
30
Starts
2022-03-22
Expected to finish
2037-02-01
Last updated by the study team
2025-05-22

Who can join

Age: 0 and older, up to 35. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.